CYPHERPUNK TECHNOLOGIES INC. Operating Lease, Right-of-Use Asset, Amortization Expense
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $224.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-12
- CYPHERPUNK TECHNOLOGIES INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $114.00K, a 11.76% increase year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-03-31 was $110.00K, a 10.00% increase year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $224.00K, a 46.02% decline from fiscal 2024.
- CYPHERPUNK TECHNOLOGIES INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $415.00K, a 0.73% increase from fiscal 2023.
- CYPHERPUNK TECHNOLOGIES INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $412.00K, a 3.26% increase from fiscal 2022.
- CYPHERPUNK TECHNOLOGIES INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $399.00K, a 1.79% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $114.00K derived: sum of 3 quarters · filed 2026-08-12 | $224.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $114.00K derived: sum of 2 quarters · filed 2026-08-12 | $224.00K 10-Q · filed 2025-11-12 | $332.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $114.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $224.00K 10-Q · filed 2026-08-12 | $332.00K derived: sum of 3 quarters · filed 2026-08-12 | $437.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $110.00K 10-Q · filed 2026-05-14 | $218.00K derived: sum of 2 quarters · filed 2026-05-14 | $323.00K derived: sum of 3 quarters · filed 2026-05-14 | $425.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $108.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $213.00K derived: sum of 2 quarters · filed 2026-03-16 | $315.00K derived: sum of 3 quarters · filed 2026-03-16 | $415.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | $105.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $207.00K derived: sum of 2 quarters · filed 2025-11-12 | $307.00K 10-Q · filed 2025-11-12 | $413.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $102.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $202.00K 10-Q · filed 2025-08-14 | $308.00K derived: sum of 3 quarters · filed 2025-08-14 | $412.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $100.00K 10-Q · filed 2025-05-13 | $206.00K derived: sum of 2 quarters · filed 2025-05-13 | $310.00K derived: sum of 3 quarters · filed 2025-05-13 | $412.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $210.00K derived: sum of 2 quarters · filed 2025-03-26 | $312.00K derived: sum of 3 quarters · filed 2025-03-26 | $412.00K 10-K · filed 2025-03-26 |
| 2023-09-30 | $104.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $206.00K derived: sum of 2 quarters · filed 2023-11-13 | $306.00K 10-Q · filed 2023-11-13 | $403.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-06-30 | $102.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $202.00K 10-Q · filed 2023-08-14 | $299.00K derived: sum of 3 quarters · filed 2024-05-13 | $395.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-03-31 | $100.00K 10-Q · filed 2024-05-13 | $197.00K derived: sum of 2 quarters · filed 2024-05-13 | $293.00K derived: sum of 3 quarters · filed 2024-05-13 | $395.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $97.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $193.00K derived: sum of 2 quarters · filed 2024-03-18 | $295.00K derived: sum of 3 quarters · filed 2024-03-18 | $399.00K 10-K · filed 2024-03-18 |
| 2022-09-30 | $96.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $198.00K derived: sum of 2 quarters · filed 2023-11-13 | $302.00K 10-Q · filed 2023-11-13 | $477.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $102.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $206.00K 10-Q · filed 2023-08-14 | $381.00K derived: sum of 3 quarters · filed 2023-08-14 | $407.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $104.00K 10-Q · filed 2023-05-15 | $279.00K derived: sum of 2 quarters · filed 2023-05-15 | $305.00K derived: sum of 3 quarters · filed 2023-05-15 | $401.00K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $175.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $201.00K derived: sum of 2 quarters · filed 2023-03-24 | $297.00K derived: sum of 3 quarters · filed 2023-03-24 | $392.00K 10-K · filed 2023-03-24 |
| 2021-09-30 | $26.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $122.00K derived: sum of 2 quarters · filed 2022-11-14 | $217.00K 10-Q · filed 2022-11-14 | $310.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $96.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $191.00K 10-Q · filed 2022-08-12 | $284.00K derived: sum of 3 quarters · filed 2022-08-12 | $375.00K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $95.00K 10-Q · filed 2022-05-13 | $188.00K derived: sum of 2 quarters · filed 2022-05-13 | $279.00K derived: sum of 3 quarters · filed 2022-05-13 | |
| 2020-12-31 | $93.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $184.00K derived: sum of 2 quarters · filed 2022-03-11 | $499.00K 10-K · filed 2022-03-11 | |
| 2020-09-30 | $91.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $406.00K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $315.00K 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |